Some venture investors are already modelling scenarios where otherwise viable Australian biotechs either move key programmes overseas or shut down completely.
The new measure sits in a little-noticed paragraph of the budget papers and tightens access to the refundable Research and Development Tax Incentive for firms older than 10 years. The Albanese government is pitching the carve-out as a way to focus generous support on younger high-growth innovators rather than more mature companies.
Under the plan, once a biotech passes its 10th birthday it would lose eligibility for the fully refundable component, a critical source of non-dilutive capital. That change lands hardest on companies still in pre-revenue clinical development, where projects can run for many years.
One of the clearest examples is Melbourne-based Cartherics, a biotech developing off-the-shelf cell therapies targeting ovarian cancer, triple negative breast cancer and endometriosis. The company recently completed a specialised manufacturing facility for gene-modified immune cells, a major capital investment that assumed ongoing support from the R&D rebate.
Cartherics is also preparing to launch its first clinical trial in ovarian cancer patients later this year, a phase when R&D spending spikes and cash burn accelerates. It marked its 10th anniversary only last month, which suddenly places its future refundable tax support in doubt at the exact moment costs climb.
The clash between policy design and biotech reality exposes a gap in how long it actually takes to turn medical research into commercial products. Drug development commonly stretches well beyond a decade, especially for complex immunotherapies that demand heavy infrastructure and multi-stage trials.
Industry groups argue the budget wording misunderstands that timeline, effectively penalising companies that have survived the riskiest early years but are not yet earning revenue. The tension centres on whether the government adjusts the 10-year cut-off or risks watching Australian-developed therapies and jobs migrate to more predictable regimes overseas.
